A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2018
At a glance
- Drugs CPI 613 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 23 Dec 2016 Status changed from active, no longer recruiting to completed.
- 12 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.